This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Please amend claim 18 and add new claims 30-34 as follows:

- 1-17. (Canceled)
- 18. (Currently Amended) A method of treating leukemia, colon cancer, breast cancer or prostate cancer comprising administering to a patient with said disease leukemia an effective amount of 2-methylene-19-nor-20(S)- 1α ,25-dihydroxyvitamin D₃ having the formula:

- 19. (Original) The method of claim 18 wherein 2-methylene-19-nor-20(S)- 1α ,25-dihydroxyvitamin D₃ is administered orally.
- 20. (Original) The method of claim 18 wherein 2-methylene-19-nor-20(S)- 1α ,25-dihydroxyvitamin D₃ is administered parenterally.
- 21. (Original) The method of claim 18 wherein 2-methylene-19-nor-20(S)- 1α ,25-dihydroxyvitamin D₃ is administered transdermally.
- 22. (Original) The method of claim 12 wherein 2-methylene-19-nor-20(S)- 1α ,25-dihydroxyvitamin D₃ is administered in a dosage of from about $0.01\mu g/day$ to about $10 \mu g/day$.

23-29. (Canceled)

30. (New) A method of treating colon cancer, breast cancer or prostate cancer comprising administering to a patient with said disease an effective amount of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D₃ having the formula:

- 31. (New) The method of claim 30 wherein 2-methylene-19-nor-20(S)- 1α ,25-dihydroxyvitamin D₃ is administered orally.
- 32. (New) The method of claim 30 wherein 2-methylene-19-nor-20(S)- 1α ,25-dihydroxyvitamin D₃ is administered parenterally.
- 33. (New) The method of claim 30 wherein 2-methylene-19-nor-20(S)- 1α ,25-dihydroxyvitamin D₃ is administered transdermally.
- 34. (New) The method of claim 30 wherein 2-methylene-19-nor-20(S)- 1α ,25-dihydroxyvitamin D₃ is administered in a dosage of from about $0.01\mu g/day$ to about 10 $\mu g/day$.